FDA Seeks to Speed Insulin Biosimilar Approvals with New Guidance

In a move to help sponsors of insulin biosimilar applications, the FDA spelled out the data and information needed to support immunogenicity assessments for insulin biosimilars or interchangeables in a draft guidance released on Monday.
Source: Drug Industry Daily